Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers April 16, 2026 by Mathieu Maurice Mabwell (688062.SH), an innovation-focused biopharmaceutical company with an integrated value chain, has announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its …
